HPV infection is recognized as the necessary cause of precancerous cervical lesions and cervical cancers and is the most common sexually transmitted disease affecting about 400 million women worldwide. Most infections are spontaneously eliminated in less than one year.
The terms of agreement include Roche’s leadership in the worldwide development and commercialization of Transgene's lead therapeutic vaccine candidate TG 4001 (MVA-HPV-IL2), currently under clinical development for the treatment of high grade cervical intraepithelial neoplasia (CIN2/3) - a precancerous cervical abnormality which can lead to cervical cancer.
According to Philippe Archinard, Chief Executive Officer of Transgene:
Find more details of the terms of agreement from the full press release (a pdf file).“We are delighted by Roche's commitment to further develop our promising vaccine TG 4001 in the field of HPV-mediated diseases. Roche has broad expertise and a leadership position in the development and marketing of first-in-class innovative therapies.
This first strategic partnership is an acknowledgement of the validity of our technology and strategy. It is a considerable transforming event for Transgene that we anticipate will enable us to accelerate and broaden the development of our entire product portfolio.”
Comment Preview